(ANSA) – GENOA, APRIL 12 – The consolidated revenues of Esaote, a leading biomedical company in the fields of diagnostic imaging, from ultrasound to magnetic resonance imaging and IT for healthcare, in 2021 rose to 231.1 million euros, with a growth of 5% compared to 2020, and order collection increased by 18%. The managing director Franco Fontana announced the first results of the 2021 financial statements “of which we are extremely satisfied” approved by the board of directors of Esaote. And for 2022 he anticipates: “We have very ambitious growth objectives. It is not a dream, but the consequence of the actions taken”. In support of the forecasts there is precisely the consistent order collection at the end of 2021 which is continuing and the goal of “launching at least two new products per year over the next three years”. Returning to the balance sheet “In 2020 we made a positive result – explains Fontana – but very focused on the main business, because the demand was above all on ultrasound instruments, due to the need to fight Covid with simple, fast and flexible tools that could be carried even in intensive care and first aid. In 2021 we had a homogeneous growth on all lines: ultrasounds + 5%, magnetic resonance, extremely penalized in 2020, in 2021 it exploded with 40% more sales, helped also since the launch of the new product at the end of the year, Esaote’s first open total body magnetic resonance imaging and Information technology It grew by almost 7% “. A growth that affected all the strategic markets of the group while 2020 was more patchy, with “great progress also on international markets which make up 70% of total revenues”.
(HANDLE).
Source: Ansa
I have been working in the news industry for over 10 years now and I have worked for some of the biggest news websites in the world. My focus has always been on entertainment news, but I also cover a range of other topics. I am currently an author at Global happenings and I love writing about all things pop-culture related.
